Skip to main content
Valbiotis logo

Valbiotis — Investor Relations & Filings

Ticker · ALVAL ISIN · FR0013254851 LEI · 969500VP4JBJCF0MOP60 PA Manufacturing
Open in API
Filings indexed 428 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country FR France
Listing PA ALVAL

About Valbiotis

https://www.valbiotis.com/en/

Valbiotis is a research and development company that develops and commercializes plant-based dietary supplements for the prevention and management of metabolic diseases. The company's portfolio is centered on its patented "TOTUM" line of active substances, which undergo rigorous clinical trials to validate their efficacy. Key products include TOTUM•63 for reducing blood glucose in prediabetic individuals, TOTUM•448 for cardio-liver health, and TOTUM•854 for managing blood pressure. Valbiotis provides scientifically proven, natural, non-drug solutions and is transitioning from a research-focused model to a commercial-stage enterprise.

Recent filings

Filing Released Lang Actions
VALBIOTIS SA: Monacolins from Red Yeast Rice: On May 13, EU Member States voted in favor of the draft regulation aimed at banning monacolins from red yeast rice
Regulatory Filings Classification · 85% confidence The document is a corporate press release by Valbiotis describing an EU regulatory vote and its strategic impact. It does not contain financial statements or detailed report data, nor does it announce the publication of a formal report. It is a general regulatory announcement to investors/market. Therefore it falls under the general Regulatory Filings category.
2026-05-27 English
VALBIOTIS SA: Monacolines de levure de riz rouge : les États membres ont émis un vote favorable sur le projet de règlement européen le 13 mai visant à interdire les monacolines de levure de riz rouge
Regulatory Filings Classification · 82% confidence The document is a corporate press release announcing a recent EU regulatory vote and potential future regulation banning monacolines in red yeast rice. It does not contain financial results, specific share transactions, proxy materials, or offer detailed governance/annual report content. It is not certifying or attaching any formal report but simply communicates regulatory news, making it a general regulatory announcement best classified under RNS (Regulatory Filings).
2026-05-27 French
VALBIOTIS SA: Monacolins from Red Yeast Rice: On May 13, EU Member States voted in favor of the draft regulation aimed at banning monacolins from red yeast rice
Regulatory Filings Classification · 87% confidence The document is a press release announcing a regulatory development (EU draft regulation banning monacolins from red yeast rice) and its strategic impact for Valbiotis. It does not contain financial statements, management discussion or voting results, nor is it an AGM or earnings release. It is a general regulatory announcement distributed via a regulatory news service (EQS). Therefore it falls under Regulatory Filings (RNS).
2026-05-27 English
VALBIOTIS SA: Valbiotis continues its expansion in Asia
Regulatory Filings Classification · 30% confidence The document is a corporate press release announcing the creation of a new subsidiary in Singapore via a joint venture, outlining business expansion and commercial launch plans. It contains no financial statements, no regulatory certification of a report, no share issuance or repurchase details, no dividend notice, no earnings figures, and no governance or M&A bid. It is a general business update and thus falls under the fallback category for miscellaneous regulatory announcements.
2026-05-11 English
VALBIOTIS SA: Valbiotis poursuit son déploiement en Asie
Regulatory Filings Classification · 75% confidence The document is a press release (“communiqué de presse”) announcing the creation of a new subsidiary in Singapore by a Chinese joint venture and outlining the company’s business expansion in Asia. It contains no financial results, no specific report attachments, no regulatory certifications, no share transactions, and no invitation to vote or vote results. It is not an investor presentation, earnings release, management report, or interim/annual report. Therefore, it fits best into the fallback category for general corporate/regulatory announcements. Classification: Regulatory Filings (RNS).
2026-05-11 French
VALBIOTIS SA: Valbiotis continues its expansion in Asia
Regulatory Filings Classification · 90% confidence The document is a French Regulatory News press release (inside information) announcing the business expansion of Valbiotis in Asia. It contains no financial statements, management changes, capital transactions, or results. It is a general corporate announcement distributed via a regulatory news service. It therefore falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-05-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.